FDA Recalls Blood Pressure Medication Over Carcinogen Concerns
The U.S. Food and Drug Administration (FDA) has announced significant recalls of the blood pressure medication prazosin hydrochloride due to concerns over potential carcinogen contamination. Over 580,000 bottles of prazosin capsules, produced by New Jersey-based Teva Pharmaceuticals USA and distributed by Amerisource Health Services, are being withdrawn from the market.
Details of the Recall
The voluntary recalls were initiated earlier this month and involve various strengths of prazosin capsules. The FDA classified the affected drug lots as having a Class II risk. This classification indicates that the recalled medications may contain nitrosamine impurities, which could pose cancer risks.
About Prazosin
Prazosin is commonly prescribed to manage high blood pressure. Additionally, it is used to alleviate nightmares and sleep disturbances associated with post-traumatic stress disorder (PTSD). The medication works by relaxing blood vessels, thus improving blood flow.
Health Implications
- N-nitrosamine impurities: These chemicals can form during the production or storage of pharmaceuticals and are known for their carcinogenic potential.
- FDA’s action: The FDA encourages patients taking the affected medication to consult their healthcare providers for alternatives.
Patients and healthcare professionals are urged to pay attention to this recall to prevent possible health risks associated with the contaminated medication.
